Metformin vs Glipizide: A Comprehensive Comparison for Type 2 Diabetes
Introduction
Type 2 Diabetes Mellitus (T2DM) affects over 77 million adults in India, making it the diabetes capital of the world. The choice between metformin and sulfonylureas like glipizide remains a critical clinical decision. This article examines the latest evidence comparing these two agents.
Mechanism of Action
Metformin works primarily by reducing hepatic glucose production and improving insulin sensitivity in peripheral tissues. It activates AMP-activated protein kinase (AMPK), a key cellular energy sensor.
Glipizide, a second-generation sulfonylurea, stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Written by
Dr. Priya Sharma
PharmD, PhD Clinical Pharmacology
Clinical pharmacologist with 10+ years of experience in drug safety evaluation. Currently a faculty member at NIPER Mohali.
Responses (0)
Log in to share your thoughts